{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Junyu Xu"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0010046000"],"submitter_email":["jyxu@simm.ac.cn"],"submitter_affiliation":["Shanghai Institute of Materia Medica, Chinese Academy of Sciences"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"pubmed_abstract":["<b>Background/Objectives</b>: Hepatocellular carcinoma (HCC) remains a significant global health concern, primarily due to the limited efficacy of targeted therapies, which are often compromised by drug resistance and adverse side effects. <b>Methods</b>: In this study, we utilized a Tandem Mass Tag (TMT)-based quantitative proteomic approach to analyze global protein expression and serine/threonine/tyrosine (S/T/Y) phosphorylation modifications in HepG2 cells following treatment with three clinically relevant hepatocellular carcinoma-targeted agents: apatinib, regorafenib, and lenvatinib. <b>Results</b>: Utilizing KEGG pathway enrichment analysis, biological process enrichment analysis, and protein interaction network analysis, we elucidated the common and specific metabolic pathways, biological processes, and protein interaction regulatory networks influenced by three liver cancer therapeutics. The study additionally proposed potential combinational treatment strategies, highlighting a possible synergistic interaction between HCC-targeted drugs and the DNA methyltransferase inhibitor. Furthermore, through the integration of clinical phosphorylation site data, we identified several phosphorylation sites that exhibited higher abundance in tumor tissues compared to adjacent non-tumor tissues. These sites were associated with poor prognosis and elevated functional scores. <b>Conclusions</b>: In summary, this study conducted an in-depth analysis of the molecular alterations in proteins and phosphorylation modifications induced by clinical HCC-targeted drugs, predicting drug combination strategies and therapeutic targets."],"pubmed_title":["Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma."],"pubmed_authors":["Long Hezhou H, Zhou Jiafu J, Zhou Changxia C, Xie Shuyu S, Wang Jingling J, Tan Minjia M, Xu Junyu J"],"additional_accession":[]},"is_claimable":false,"name":"Proteomic analysis of liver cancer under drug treatment","description":"we employed a tandem mass spectrometry-based quantitative proteomics strategy to perform a comprehensive analysis of protein expression profiles in the HepG2 following treatment with three clinically relevant liver cancer drugs, identifying a total of 8,036 proteins.","dates":{"publication":"Wed Oct 23 00:00:00 BST 2024"},"accession":"PXD057086","cross_references":{"TAXONOMY":["9606"],"pubmed":["39857736"]}}